Gilead's Emvistegrast Hits 23% Remission in UC Trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Emvistegrast (Gilead's oral pill) produced a 23% placebo-adjusted clinical remission rate in patients with moderate to severe ulcerative colitis after 12 weeks at a 200-milligram daily dose in a Phase 2 trial.
- The Phase 2 result was statistically significant and exceeded Wall Street analyst expectations, according to the Monday data report.
- Swati Tole, Gilead's senior vice president overseeing inflammatory disease clinical development, told STAT the drug "has the potential to be a best-in-class oral for patients with ulcerative colitis," noting most IBD patients fail to achieve remission on existing therapies.
- The mid-stage readout supports Gilead's broader push to build a pipeline of new drugs for inflammatory and autoimmune conditions, where persistent symptoms remain common despite available treatments.
- Emvistegrast is delivered as an oral pill, distinguishing it from biologic ulcerative colitis treatments that require injection or infusion.
Why it matters: Gilead's 23% placebo-adjusted remission beat analyst forecasts, giving the company a credible oral option in a UC market dominated by injectable biologics — and if Phase 3 holds up, emvistegrast could pressure existing IBD therapies that still leave a majority of patients symptomatic.
Ask SkimNews
